SAR Journal of Psychiatry and Neuroscience

Abbreviated Key Title: *SAR J Psychiatry Neurosci*
Home page: https://sarpublication.com/journal/sarjpn/home
DOI: 10.36346/sarjpn.2022.v03i03.003

ISSN 2707-7764 (P)
ISSN 2709-6939 (O)

Original Research Article

Literature Review: Drug Therapy in Ischemic Stroke Patients

Nabila Safira[1*], Muhammad Tholhah 'Azam[2]
[1]Faculty of Medicine, University of Muhammadiyah Malang, Indonesia
[2]Muhammadiyah Hospital, Lumajang, Indonesia

***Corresponding Author:** Nabika Safira
Faculty of Medicine, University of Muhammadiyah Malang, Indonesia

Article History: | Received: 29.08.2022 | Accepted: 08.10.2022 | Published: 11.10.2022 |

Abstract: ***Background:*** Ischemic stroke is the foremost common cause of stroke around the world, bookkeeping for 10 times more strokes than hemorrhagic strokes in higher pay nations. There are proof accessible for each antiplatelet sedate utilized in the treatment of ischemic stroke. The advertised recommendations for elective restorative choices when confronted with repetitive stroke. ***Aim:*** To know the use of antiplatelet in ischemic stroke patients. ***Method:*** This study used a systematic review that searched using the keyword Antiplatelet and Ischemic Stroke in Google Scholar, Crossref, and PubMed. Recent studies in English published in 2012-2022. ***Result:*** After the final screening, the author analyzed 4 articles that were published after the year 2012. ***Conclusion:*** In spite of the fact that great proof exists for the utilization of certain antiplatelet operators for postischemic stroke, there are significant openings for future investigation to examine personalized treatments. These incorporate screening patients for platelet polymorphisms that bestow antiplatelet resistance and for randomized trials counting more racially different populations.

Keywords: Antiplatelet; ischemic stroke; systematic review.

1. INTRODUCTION

Stroke is the moment most common cause of passing around the world and one of the driving causes of long- term inability all-inclusive [1]. Over the final 25 long times, there has been a worldwide diminishment in the rate of passing and age-adjusted stroke predominance, but generally, the supreme numbers of stroke cases have expanded as populaces have created a more noteworthy life span [1]. Ischemic stroke is, by distant, the foremost common cause of stroke around the world, bookkeeping for 10 times more strokes than hemorrhagic strokes in higher pay nations [2], but with much less contrast watched in lower-wage nations [3], even though the rate of stroke passings is diminishing, it is accepted that up to 50% of stroke-related passings are inferable to ineffectively overseen modifiable hazard variables [4]. Administration of hypertension, hypercholesterolemia, diabetes, smoking, and cardiac arrhythmias such as atrial fibrillation all has an impressive proof base for decreasing stroke events and repeats [5].

The hazard of repetitive ischemic stroke occasions within the to begin with 30 days is tall with 1 in 25 individuals having a repetitive stroke in this time outline [6]. In this manner, medications utilized to diminish this beginning chance can have an impressive effect on diminishing dreariness and mortality. Antiplatelet specialists are shown when the cause of the ischemic stroke is decided to be non-cardioembolic antiplatelets alter the chance of encouraging stroke occasions and decrease the rate of passing in this acute period and within the long term [7].

The foremost utilized antiplatelet specialists around the world incorporate headache medicine, clopidogrel, and dipyridamole [8]. All have a high-level proof for the avoidance of stroke repeat. Shockingly, there's a populace of patients who show “resistance” to these medicines (have ischemic occasions whereas on an antiplatelet specialist), create unfavorable impacts from utilizing, or create unfavorably susceptible responses [9]. Combining antiplatelets is related to the expanded hazard of dying when utilized for long-term avoidance, even though this expanded chance is often exceeded by diminished stroke repeat within the brief term [10, 11]. As a result, the treatment supplier is confronted with a troublesome choice around how best to treat a quiet with encouraged stroke occasions who has as of now gotten one antiplatelet operator.

The course of drugs that have antiplatelet movement is huge with a differing set of unthinking activities. This offers the opportunity to utilize elective antiplatelet specialists if a persistent has an ischemic stroke whereas on first-line treatments. The choice approximately which antiplatelet specialist to utilize when a more commonly utilized sedate has undesired impacts is troublesome due to constrained information comparing antiplatelet operators head-to-head [10].

In this survey article, we have summarized the proof accessible for each antiplatelet sedate utilized in the treatment of ischemic stroke. We have at that point advertised recommendations for elective restorative choices when confronted with repetitive stroke. We conclude with a description of what the long haul may hold for antiplatelet treatments in ischemic stroke.

2. METHOD

Articles were assembled from Google Scholar, Crossref, and PubMed databases. The writing look included all articles distributed between January 2012 and September 2022. Abstracts from logical gatherings were considered. Look terms included ischemic stroke and antiplatelet drugs. Consider determination was restricted to English-language unique and audit articles. Rules from America, Joined together Kingdom, Canada, and China were looked into. When displaying clinical information on each antiplatelet operator, we have centered on randomized control trials (RCT) or efficient audit levels of proof.



Figure 1: Flowchart of search results

3. RESULT

Table 1: Antiplatelet use in ischemic stroke

Author	Year	Method	Result
F Shahid [24]	2013	Review article	The utilization of clopidogrel, which is as of now built up as an adjuvant to ibuprofen treatment, maybe a implies by individuals with biochemical ATF can have a progressed forecast. Indeed in spite of the fact that information recommends that higher doses may not be advantageous, at the display, there's small elective to this approach. In due course, in any case, it appears that ticagrelor will take over the part of clopidogrel.
Meng Lee [12]	2017	We looked at PubMed (1966 to Eminent 2016) and reference indices of pertinent distributed unique think about	Among patients who encounter an ischemic stroke or transitory ischemic assault whereas on ibuprofen

Author	Year	Method	Result
		to recognize randomized trials and cohort thinks about announcing patients who were on headache medicine at the time of a record ischemic stroke or transitory ischemic assault and detailed risk proportion for major antagonistic cardiovascular occasions or repetitive stroke related with a switch to or expansion of another antiplatelet specialist versus keeping up ibuprofen monotherapy. Gauges were combined by employing an irregular impact demonstrates.	monotherapy, the expansion of or a switch to another antiplatelet operator, particularly within the beginning with days after list occasion, is related to fewer future vascular occasions, counting stroke.
Jacoba P Greving [31]	2019	We did an organized meta-analysis (NMA) of information from 6 randomized trials of the impacts of commonly endorsed antiplatelet specialists within the long-term (≥3 months) auxiliary avoidance of non-cardioembolic stroke or transitory ischemic assault. Person understanding information from 43 112 patients was pooled and reanalyzed. Fundamental results were genuine vascular occasions (nonfatal stroke, nonfatal myocardial dead tissue, or vascular passing), major dying, and net clinical advantage (genuine vascular occasion or major dying). Subgroup investigations were done agreeing to age, sex, ethnicity, hypertension, qualifying determination, sort of vessel included (expansive versus little vessel infection), and time from qualifying occasion to randomization.	Comes about favor clopidogrel and aspirin/dipyridamole combination for long-term auxiliary avoidance after non-cardioembolic stroke or temporal ischemic assault, in any case of quiet characteristics. The aspirin/clopidogrel combination was related to an essentially higher chance of major dying compared with other antiplatelet regimens.
Devin L Brown [17]	2021	The Medline, Embase, and Cochrane databases were looked at on December 5, 2019, to recognize stage III or IV randomized controlled trials (n≥100) from December 1999 to December 2019. We calculated unadjusted relative dangers (RRs) and performed meta-analyses of things based on the length of treatment (brief [≤90 days] versus long [>90 days]).	DAPT was more compelling than SAPT for anticipation of auxiliary ischemic stroke when started early after the onset of minor stroke/high-risk temporal ischemic assault and the treatment term was <90 days. Be that as it may, when the treatment term was longer and started afterward after stroke or transitory ischemic assault onset, DAPT was not more viable than SAPT for ischemic stroke anticipation and it expanded the hazard of dying.
Philip M Bath [18]	2018	We did a universal, planned, randomized, open-label, blinded-endpoint trial in grown-up members with ischaemic stroke or temporal ischaemic assault (TIA) within 48 h of onset. Members were doled out in a 1:1 proportion utilizing computer randomization to get loading dosages and after that 30 days of seriously antiplatelet treatment (combined ibuprofen 75 mg, clopidogrel 75 mg, and dipyridamole 200 mg twice every day) or guideline-based treatment (comprising either clopidogrel alone or combined ibuprofen and dipyridamole). Randomization was stratified by nation and record occasion and limited to prognostic standard variables, pharmaceutical utilization, and time to randomization, stroke-related components, and thrombolysis.	3096 members (1556 within the seriously antiplatelet therapy bunch, 1540 within the rule antiplatelet treatment gather) were enlisted from 106 healing centers in four nations between April 7, 2009, and Walk 18, 2016. The trial ceased early on the suggestion of the information checking committee. The frequency and seriousness of repetitive stroke or TIA did not contrast between seriously and rule treatment (93 [6%] members vs 105 [7%]; balanced common chances proportion [cOR] 0·90, 95% CI 0·67-1·20, p=0·47). By contrast, intensive antiplatelet treatment was related to increasingly, serious, dying (balanced cOR 2·54, 95% CI 2·05-3·16, p<0·0001). Among patients with later cerebral ischemia, serious antiplatelet treatment did not diminish the frequency and seriousness of repetitive stroke or TIA but did altogether increment the chance of major dying. Triple antiplatelet treatment ought to not be utilized in scheduled clinical hone.
S Claiborne Johnston [11]	2020	We conducted a randomized, placebo-controlled, double-blind trial including patients who had had a mild-to-moderate intense non-cardioembolic ischemic stroke, with a National Establishing of Wellbeing Stroke Scale (NIHSS) score of 5 or less (run, to 42, with higher scores demonstrating more serious stroke), or TIA and who were not experiencing thrombolysis or thrombectomy. The patients were doled out inside 24 hours after side effect onset, in a 1:1 proportion, to get a 30-day regimen of either ticagrelor (180-mg stacking measurements taken after by 90 mg twice day by day) furthermore ibuprofen (300 to 325 mg on the primary day taken after by 75 to 100 mg every day) or coordinating fake treatment also headache medicine. The essential result was a composite of stroke or passing within 30 days. Auxiliary results were, to begin with, consequent ischemic stroke and the rate of inability inside 30 days. The essential security result was seriously dying.	Among patients with a mild-to-moderate intense non-cardioembolic ischemic stroke (NIHSS score ≤5) or TIA who were not experiencing intravenous or endovascular thrombolysis, the hazard of the composite of stroke or passing inside 30 days was lower with ticagrelor-aspirin than with ibuprofen alone, but the frequency of inability did not vary altogether between the two bunches. Extreme dying was more visits with ticagrelor.

4. DISCUSSION

Stroke Whereas on Antiplatelet Therapy

The rules suggest headache medicine, either alone or in combination with dipyridamole, or clopidogrel, in non- cardioembolic stroke and TIA. Be that as it may, no antiplatelet specialist was 100% successful in anticipating repetitive cerebrovascular occasions within the clinical trials. Moreover, the marvel of antiplatelet resistance has been well-described [9]. While a meta-analysis of observational thinks was found to prove in favor of exchanging to a completely unused antiplatelet combination after a repetitive occasion, with a diminished frequency of cardiovascular occasions on follow-up [12], there are no randomized controlled trials to direct clinicians.

There are moreover a few other conceivable outcomes that ought to be investigated on the off chance that a persistent contains a stroke in spite of first-line antiplatelet treatment. To begin with, it is imperative to guarantee that the persistent is adherent to the antiplatelet as prescribed [13]. Moment, a concurrent medicine audit may uncover association drugs that ought to be evacuated. In case, omeprazole can unfavorably influence the clopidogrel digestion system, if a proton pump inhibitor (PPI) is required, lansoprazole or an elective PPI should be endorsed instead [14]. Third, antiplatelet treatment disappointment ought to provoke the doctor to rummage around for cardioembolic causes of stroke that may react to anticoagulants instead of antiplatelet specialists.

At last, there may be ways to optimize auxiliary anticipation instead of exchanging antiplatelets, for illustration, expanding the dosage of statin or making strides in blood weight and/or blood glucose control. Way of life adjustments ought to moreover be forcefully overseen in patients who have had a stroke, as there's solid proof from the Stenting and Forceful Therapeutic Administration for Anticipating Repetitive Stroke in Intracranial Stenosis (SAMMPRIS) consider that physical action anticipates encouraging vascular events [15]. In patients who performed standard physical activities such as strolling, the chances proportion of an assist vascular occasion (repetitive stroke, myocardial dead tissue, or vascular passing) was 0.6 (95% CI = 0.4-0.8) compared with those who did not.

An imperative thought is that an extent of patients has hereditary polymorphisms rendering their platelets safe from the impacts of certain antiplatelets. A few point-of-care testing (POCT) units are presently accessible to identify these polymorphisms, but the testing packs themselves require advance approval sometime recently joining into randomized trials [9]. Until that point, it is hazy how POCT can be utilized to direct the primary choice of antiplatelet, or later switching of antiplatelets within the confront of repetitive occasions.

Thought of Double Antiplatelet Therapy

As talked about already in this article, there have been various thinks about comparing DAPT with single antiplatelet administrations for different timeframes. The utilization of DAPT inside the primary 21 days poststroke does offer an extra advantage for patients with mellow stroke or high-risk TIA [16]. Once more, the biggest body of proof comes for the utilization of clopidogrel and headache medicine in combination. A later AHA/ASA meta-analysis of double versus single antiplatelet treatment for stroke anticipation in patients with ischemic stroke or TIA concluded that short-duration DAPT (up to 90 days) started before long after the file occasion decreased the chance of repetitive stroke (RR = 0.68, 95% CI = 0.55-0.83), with no critical increment in major dying. In differentiate; long-term DAPT expanded the chance of major dying with no decrease in repetitive stroke risk [17].

The part of triple antiplatelet treatment has to be inspected. The TARDIS trial (n = 3096), which was ceased early on security and worthlessness grounds, found that 30 days of a seriously antiplatelet administration (ibuprofen, clopidogrel, and dipyridamole) carried altogether higher dying dangers, with no commensurate diminishment in stroke repeat, compared with standard treatment of clopidogrel or ibuprofen and dipyridamole [18].

Headache medicine and dipyridamole have appeared to have viability as long-term auxiliary avoidance, but within the intense setting, DAPT comprised of ibuprofen and clopidogrel remains the combination of choice. The Declare trial inspected long-term DAPT (headache medicine and dipyridamole) versus clopidogrel and found no distinction in stroke repeat rates, but higher rates of dying within the DAPT group [19]. While ticagrelor isn't authorized for stroke within the Joined together Kingdom, the THALES think about found that DAPT with headache medicine brought about in fewer strokes at 30 days compared with headache medicine alone but came with a somewhat higher dying risk [20].

Interests, in a later arrange meta-analysis, the utilize of ibuprofen and clopidogrel (HR = 0.74, 95% CI = 0.65- 0.84, n = 5517) or ibuprofen and ticagrelor (HR = 0.79, 95% CI = 0.68-0.91, n = 5853) was compared with headache medicine alone (n = 10,722) and found that both DAPT administrations were prevalent to ibuprofen alone at anticipating repetitive stroke or passing up to 90 days post-treatment start. This once more even though was at the cost of an expanded chance of major hemorrhage.

The current agreement is that DAPT is fitting within the acute phase (characterized as the primary 30 days poststroke) postischemic stroke, particularly when started instantly, but there shows up to be no advantage

in proceeding this further [16]. Rules from a few nations, counting the Joined together States, Joined together Kingdom, and China, suggest commencing DAPT with headache medicine furthermore clopidogrel within 24 hours of minor stroke (characterized as NIHSS ≤3) or high-risk TIA (characterized as ABCD2 ≥ 4, the ABCD2 score being a gauge of stroke hazard after TIA based on patients age, blood weight, clinical highlights, length of indications, and nearness of diabetes) and proceeding for 21 days [21-23].

This is often to a great extent based on the CHANCE and POINT trials that appeared that DAPT with headache medicine furthermore clopidogrel for up to 21 days leads to a critical decrease in repetitive ischemic stroke at 90 days compared with ibuprofen monotherapy (RR = 0.70, 95% CI = 0.61-0.8, NNT = 53), n = 10 301.11,89 Assist work seem to explore utilizing a few distinctive combinations of antiplatelet operators which have not been trialed to date.

Significance to Understanding Care and Clinical Practice

Several techniques might be considered to move forward the utilization of antiplatelet specialists within the treatment of stroke in future investigation trials and clinical hone. It shows up that within the tremendous lion's share of cases, the long-term auxiliary avoidance of stroke is best managed using either clopidogrel or headache medicine. Within the intense setting, there are a few issues that possibly may well be made strides utilizing elective antiplatelet operators. When considering these issues, the application of a personalized medicine approach to the treatment of stroke with antiplatelets ought to be considered.

There's an expansive body of proof to recommend that certain platelet hereditary polymorphisms can render patients safe for treatment with either clopidogrel or ibuprofen. Given the solid proof base for the utilization of ibuprofen and clopidogrel in AIS and auxiliary avoidance, screening for these polymorphisms upon initial stroke introduction may be considered when personalizing the approach to antiplatelet utilization. These come about seem to illuminate whether to consider combination treatment, switch antiplatelet specialists, or increment the headache medicine dosage, even though these alternatives must be adjusted against the hazard of dying, sedate unfavorable impacts, and the plausibility of resistance to other antiplatelet drugs. The most noteworthy hazard of repetitive stroke is within the primary 30 days of the beginning occasion.

Subsequently, in future clinical settings, as hereditary phenotyping gets to be more open, this may be done as a portion of the starting stroke evaluation. This would permit the stroke doctor to at that point make a more educated choice as to which antiplatelet operator to utilize in cases of clopidogrel or ibuprofen resistance. Biochemical reaction to headache medicine and clopidogrel can be measured through in vitro tests such as platelet work examination (PFA) tests, light transmission aggregometry, and in vivo evaluation of thromboxane metabolites. Be that as it may, there's a destitute relationship between the distinctive test comes about in each person subject.[24] The assortment of proposed components and need for an agreement concerning the best screening methodology implies that there's no current single test to dependably decide which patients are likely to involvement headache medicine treatment disappointment, in this manner requires clinical judgment approximately continuous treatment technique in case of headache medicine treatment disappointment were to happen right now.

Inside the intense setting, choices approximately the utilization of certain antiplatelets in combination with thrombolysis/thrombectomy and which combination of antiplatelets to utilize as the portion of DAPT may well be reviewed as the portion of future clinical trials. There's proof that certain antiplatelet agents may progress results when utilized in conjunction with thrombolysis within the intense setting (eptifibatide, glycoprotein IIb/IIIa inhibitor, possibly being one of these drugs). When considering the utilization of DAPT within the starting auxiliary anticipation of stroke, it ought to moreover be considered that not all combinations of antiplatelets have been inquired about, and so way better combinations may still be found.

Be that as it may, it is vital to keep in mind that there have shown up to be more hazards than advantages to expanding DAPT past 21 days. Most of the investigations for the utilization of clopidogrel and headache medicine as the portion of DAPT centers on Western and Chinese populaces; hence, it may be that patients of distinctive ethnicities react superior to other combinations of antiplatelets in this intense stage.

Race ought to too be considered when arranging future long-term treatment trials for the auxiliary anticipation of stroke. There's proof as of now that stroke sort, rate, and hazard variables contrast among ethnic groups [25], hence, auxiliary avoidance of stroke is likely to be perplexed by this. In spite of the fact that there's an exceptionally great proof for the use of clopidogrel and headache medicine within the long-term anticipation of stroke, there's a signal that other antiplatelets may have extra benefits to nonwhite populaces (cilostazol could be a potential illustration of this in Japanese populaces). Ticagrelor and prasugrel don't rely on the movement of CYP2C19 and so may moreover have expanded benefits over clopidogrel in East Asian populaces known to have a better carrier recurrence of the CYP2C19 loss-of- function allele [27].

At long last, procedures pointed at moving forward persistent adherence to endorsed drugs ought to too be considered. One of the biggest components influencing the viability of antiplatelet operators within the auxiliary anticipation of stroke is understanding nonadherence with medications [26]. It has been proposed that noncompliance with the utilization of antiplatelet specialists can be as tall as 35% twelve months postischemic stroke. There are a few variables that are thought to influence this, counting being more seasoned than the age of 70 a long time ancient, as of now taking different medicines (>4 drugs), coming from a lower social financial lesson, and being from a more provincial community [28].

In English-speaking communities, having a poorer capability in English has been related to decrease antiplatelet adherence, as has to have different therapeutic comorbidities [29]. Methodologies pointed at moving forward mindfulness of the side impacts of antiplatelet specialists, investing patients with more information around why they are taking the medicate and having get to fitting pharmaceutical counseling have appeared to be variables that can be tended to make strides quiet antiplatelet adherence [30].

5. CONCLUSION

Antiplatelet operators stay one of the foremost solid and best inquired about auxiliary preventive measures for the treatment of stroke. The utilization of both clopidogrel and ibuprofen is well built up in both the intense and auxiliary anticipation settings and is the premise of most clinical rules around the world. Even though there's as of now, great proof for the suitable utilization of antiplatelets postischemic stroke, future investigations may center on how to personalize the approach to antiplatelet medicine. This may take the frame of screening patients for platelet polymorphisms that bestow antiplatelet resistance or amplifying randomized controlled trial levels prove to be more enveloping of the different racial populaces that are influenced by stroke.

AKNOWLEDGEMENT

The author declares there is no conflict of interest.

REFERENCES

1. Feigin, V. L., Abajobir, A. A., Abate, K. H., Abd-Allah, F., Abdulle, A. M., Abera, S. F., ... & Nguyen, G. (2017). Global, regional, and national burden of neurological disorders during 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet Neurology*, *16*(11), 877-897.
2. Andersen, K. K., Olsen, T. S., Dehlendorff, C., & Kammersgaard, L. P. (2009). Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors. *Stroke*, *40*(6), 2068-2072.
3. Poon, M. T., Bell, S. M., & Salman, R. A. S. (2016). Epidemiology of intracerebral haemorrhage. *New Insights in Intracerebral Hemorrhage*, *37*, 1-12.
4. Avan, A., Digaleh, H., Di Napoli, M., Stranges, S., Behrouz, R., Shojaeianbabaei, G., ... & Azarpazhooh, M. R. (2019). Socioeconomic status and stroke incidence, prevalence, mortality, and worldwide burden: an ecological analysis from the Global Burden of Disease Study 2017. *BMC medicine*, *17*(1), 1-30.
5. Boehme, A. K., Esenwa, C., & Elkind, M. S. (2017). Stroke risk factors, genetics, and prevention. *Circulation research*, *120*(3), 472-495.
6. Hankey, G. J. (2003). Long-term outcome after ischaemic stroke/transient ischaemic attack. *Cerebrovascular diseases*, *16*(Suppl. 1), 14-19.
7. Sandercock, P. A., Counsell, C., Tseng, M. C., & Cecconi, E. (2014). Oral antiplatelet therapy for acute ischaemic stroke. *Cochrane Database of Systematic Reviews*, 2014(3), CD000029.
8. Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., ... & American Heart Association Stroke Council. (2019). Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*, *50*(12), e344-e418.
9. Topçuoglu, M. A., Arsava, E. M., & Ay, H. (2011). Antiplatelet resistance in stroke. *Expert review of neurotherapeutics*, *11*(2), 251-263.
10. Malloy, R. J., Kanaan, A. O., Silva, M. A., & Donovan, J. L. (2013). Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis. *Clinical therapeutics*, *35*(10), 1490-1500.
11. Johnston, S. C., Easton, J. D., Farrant, M., Barsan, W., Conwit, R. A., Elm, J. J., ... & Palesch, Y. Y. (2018). Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA. *New England Journal of Medicine*, *379*(3), 215-225.
12. Lee, M., Saver, J. L., Hong, K. S., Rao, N. M., Wu, Y. L., & Ovbiagele, B. (2017). Antiplatelet regimen for patients with breakthrough strokes while on aspirin: a systematic review and meta-analysis. *Stroke*, *48*(9), 2610-2613.
13. Schwartz, K. A., Schwartz, D. E., Barber, K., Reeves, M., & De Franco, A. C. (2008). Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. *Journal of Translational Medicine*, *6*(1), 1-7.
14. Allen, C., Dunn, S. P., Macaulay, T. E., & Mukherjee, D. (2010). Clopidogrel-proton pump inhibitor interaction: a primer for clinicians. *Cardiovascular & Haematological*

Disorders-Drug Targets (Formerly Current Drug Targets-Cardiovascular & Hematological Disorders), *10*(1), 66-72.
15. Turan, T. N., Nizam, A., Lynn, M. J., Egan, B. M., Le, N. A., Lopes-Virella, M. F., ... & Chimowitz, M. I. (2017). Relationship between risk factor control and vascular events in the SAMMPRIS trial. *Neurology*, *88*(4), 379-385.
16. Prasad, K., Siemieniuk, R., Hao, Q., Guyatt, G., O'Donnell, M., Lytvyn, L., ... & Rochwerg, B. (2018). Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. *Bmj*, *363*, k5130.
17. Brown, D. L., Levine, D. A., Albright, K., Kapral, M. K., Leung, L. Y., Reeves, M. J., ... & American Heart Association Stroke Council. (2021). Benefits and risks of dual versus single antiplatelet therapy for secondary stroke prevention: a systematic review for the 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack. *Stroke*, *52*(7), e468-e479.
18. Bath, P. M., Woodhouse, L. J., Appleton, J. P., Beridze, M., Christensen, H., Dineen, R. A., ... & Broughton, D. (2018). Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial. *The Lancet*, *391*(10123), 850-859.
19. Sacco, R. L., Diener, H. C., Yusuf, S., Cotton, D., Ôunpuu, S., Lawton, W. A., ... & Yoon, B. W. (2008). Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *New England Journal of Medicine*, *359*(12), 1238-1251.
20. Johnston, S. C., Amarenco, P., Denison, H., Evans, S. R., Himmelmann, A., James, S., ... & Wang, Y. (2020). Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. *New England Journal of Medicine*, *383*(3), 207-217.
21. Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., ... & Tirschwell, D. L. (2018). 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*, *49*(3), e46-e99.
22. Stroke Foundation. Clinical guidelines for stroke management 2017. Accessed December 31, 2021. https://informme.org.au/guidelines/clinical-guidelines-for-stroke-management.
23. Wang, Y., Liu, M., & Pu, C. (2017). 2014 Chinese guidelines for secondary prevention of ischemic stroke and transient ischemic attack: Compiled by the Chinese Society of Neurology, Cerebrovascular Disease Group. *International Journal of stroke*, *12*(3), 302-320.
24. Shahid, F., Chahal, C. A. A., & Akhtar, M. J. (2013). Aspirin treatment failure: is this a real phenomenon? A review of the aetiology and how to treat it. *JRSM Short Reports*, *4*(4), 1-9.
25. Sacco, R. L. (2020). Stroke disparities: from observations to actions: inaugural Edward J. Kenton lecture 2020. *Stroke*, *51*(11), 3392-3405.
26. Schwartz, K. A., Schwartz, D. E., Barber, K., Reeves, M., & De Franco, A. C. (2008). Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. *Journal of Translational Medicine*, *6*(1), 1-7.
27. Scott, S. A., Sangkuhl, K., Stein, C. M., Hulot, J. S., Mega, J. L., Roden, D. M., ... & Shuldiner, A. R. (2013). Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. *Clinical Pharmacology & Therapeutics*, *94*(3), 317-323.
28. Kim, S. J., Kwon, O. D., Choi, H. C., Lee, E. J., Cho, B., & Yoon, D. H. (2021). Prevalence and associated factors of premature discontinuation of antiplatelet therapy after ischemic stroke: a nationwide population-based study. *BMC neurology*, *21*(1), 1-11.
29. Palacio, A. M., Vidot, D. C., Tamariz, L. J., Uribe, C., Hazel-Fernandez, L., Li, H., ... & Carrasquillo, O. (2017). Can We Identify Minority Patients at Risk of Non-Adherence to Antiplatelet Medication at the time of Coronary Stent Placement?. *The Journal of cardiovascular nursing*, *32*(6), 522-529.
30. Pithara, C., Pufulete, M., Johnson, T. W., & Redwood, S. (2020). Patient perspectives of nuisance bleeding and adherence to dual antiplatelet therapy: a qualitative study. *Open heart*, *7*(2), e001405.
31. Greving, J. P., Diener, H. C., Reitsma, J. B., Bath, P. M., Csiba, L., Hacke, W., ... & Cerebrovascular Antiplatelet Trialists' Collaborative Group. (2019). Antiplatelet therapy after noncardioembolic stroke: an individual patient data network meta-analysis. *Stroke*, *50*(7), 1812-1818.